Previous 10 | Next 10 |
Pulmatrix Reports 2020 Financial Results and Provides Business Update Initiated PUR1800 Phase 1b study with data anticipated in Q4 2021 Pulmazole Ph2b study start anticipated Q1 2022 PUR3100 development candidate declared for pulmonary delivered DHE (dihydroergotamine) a...
Entera Bio Ltd. (ENTX +51% following osteoporosis drug results.ContraFect Corporation (CFRX +35% on receiving $86.8M in BARDA contract.GigaMedia Limited (GIGM) +34%.Seelos Therapeutics (SEEL +30% as BTIG initiates with street high target.Fujian Blue Hat Interacti...
Evofem Biosciences EVFM -25% on Q4 earnings release.Super League Gaming (SLGG) -19%.GSX Techedu GSX -15% on Q4 earnings release.T2 Biosystems TTOO -10% on Q4 earnings release.Senseonics Holdings SENS -9% on Q4 earnings release.Aerpio Pharmaceuticals ARP...
Pulmatrix Provides a Pipeline and Business Update PUR1800 Phase 1b study dosing is underway with data anticipated in Q4 2021 Pulmatrix completed FDA Type-C meeting and anticipates a Pulmazole Ph2b study start in Q1 2022 PUR3100 lead DHE (dihydroergotamine) formulation id...
Pulmatrix ([[PULM]] +5.4%) announces that it has closed its previously announced registered direct offering with certain healthcare-focused institutional investors for the sale of 20M shares with gross proceeds of $40M.The company intends to use the net proceeds for working capital and genera...
Pulmatrix Announces Closing of $40 Million Registered Direct Offering PR Newswire LEXINGTON, Mass. , Feb. 16, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address s...
Gainers: ESSA Pharma (EPIX) +47%. Ayala Pharmaceuticals (AYLA) +45%. GenMark Diagnostics (GNMK) +27%. ADiTx Therapeutics (ADTX) +27%. Celsion (CLSN) +26%.Losers: Tilray (TLRY) -39%. Anchiano Therapeutics (ANCN) -35%. Zynerba Pharmaceuticals (ZYNE) -28%. Pulmatrix (PULM) -26%. Aphria (APHA) -2...
Gainers: RCM Technologies (RCMT) +85%.Ayala Pharmaceuticals (AYLA) +60%.ESSA Pharma (EPIX) +45%.GenMark Diagnostics (GNMK) +29%.Castor Maritime (CTRM) +28%.Borqs Technologies (BRQS) +26%.SOS Limited (SOS) +25%.Lyra Therapeutics (LYRA) +25%.Inpixon (INPX) +25%.Quotient Technology (QUOT) +...
Anchiano Therapeutics (ANCN) -28%.Pulmatrix (PULM) -21% on direct offering.United States Antimony (UAMY) -21% on direct offering.Cancer Genetics (CGIX) -21% on stock offering.BioHiTech Global (BHTG) -15%.Fluidigm (FLDM) -14% on Q4 earnings; inks distrib...
Pulmatrix (PULM) inks agreements with institutional investors for the purchase and sale of 20M common shares at $2.00/share, in a registered direct offering.Expected gross proceeds are $40M. Net proceeds will be used for working capital and general corporate purposes.Closing date is February ...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...